$'s to continue studyIs it possible the FDA is insisting on additional research and financial backers have Spectal in a corner with little to no option to respond to negative PR. Of course there is a huge upside for the financial backers to get Spectal down as low as possible. Good thing is once Spectal has the financing it needs to tie up the loose ends with the FDA we will experience a monumental rise in the SP